Klein M D, Andrews A F, Wesley J R, Toomasian J, Nixon C, Roloff D, Bartlett R H
Ann Surg. 1985 Apr;201(4):520-6. doi: 10.1097/00000658-198504000-00019.
Venoarterial (VA) extracorporeal membrane oxygenation (ECMO) has been successful in the treatment of newborns less than 1 week of age and greater than 2000 gm birthweight with respiratory failure resistant to current medical and surgical management. While VA ECMO supports the heart as well as the lungs, it has the disadvantage of requiring carotid artery ligation and the possibility of perfusing air bubbles or particles into the arterial tree. We have treated 11 newborns with respiratory failure with venovenous (VV) ECMO returning the oxygenated blood to a cannula in the distal iliac vein. We compared these patients with 16 patients treated during the same period of time with VA ECMO. Three of the 11 VV patients required conversion to VA ECMO because of inadequate oxygenation and unstable hemodynamic situations. Ten of the 11 VV patients survived. Eleven of the 16 VA patients survived. The better survival in these patients treated with VV ECMO is attributed to their more favorable initial condition compared to patients treated with VA ECMO. The disadvantages of VV ECMO include a longer operative time to place the cannulas, groin wound problems, and persistent leg swelling along with the necessity to convert some patients to VA ECMO. Although this experience demonstrates that newborns with severe respiratory failure can be supported with VV ECMO, the complications and lack of practical advantages over VA lead us to recommend VA ECMO for routine clinical use at present.
静脉 - 动脉(VA)体外膜肺氧合(ECMO)已成功用于治疗出生体重超过2000克、年龄小于1周且对当前药物和手术治疗有抵抗的呼吸衰竭新生儿。虽然VA ECMO可同时支持心脏和肺,但它存在需要结扎颈动脉以及可能将气泡或颗粒灌注到动脉系统的缺点。我们采用静脉 - 静脉(VV)ECMO将氧合血回输至髂外静脉远端的插管,治疗了11例呼吸衰竭新生儿。我们将这些患者与同期接受VA ECMO治疗的16例患者进行了比较。11例VV患者中有3例因氧合不足和血流动力学不稳定而需要转为VA ECMO。11例VV患者中有10例存活。16例VA患者中有11例存活。与接受VA ECMO治疗的患者相比,接受VV ECMO治疗的这些患者存活率更高,这归因于他们初始状况更为良好。VV ECMO的缺点包括放置插管的手术时间更长、腹股沟伤口问题、持续的腿部肿胀以及需要将一些患者转为VA ECMO。虽然这一经验表明严重呼吸衰竭的新生儿可用VV ECMO支持,但并发症以及相较于VA缺乏实际优势,使我们目前推荐VA ECMO用于常规临床应用。